IDXX

IDEXX is a genuinely elite business and the numbers prove it. FY2025 revenue grew 10.4% to $4.30B with net income up 19.3% to $1.06B and diluted EPS up 22.6% to $13.08 — earnings compounding faster than sales because of margin leverage (operating margin 31.6%, up from a 20.5% jump in operating income) and a 2.1% reduction in share count from $1.22B of buybacks. The five-year revenue track ($3.22B→$4.30B) is steady and accelerating, and ROE of 66% is exceptional. The MD&A explains the durability: the razor/razorblade model places point-of-care VetLab and SNAP Pro instruments (installed base still climbing — Catalyst 78k, Premium Hematology 56k, the new inVue Dx already at 6k) that drag along high-margin recurring consumables and reference-lab services, which carry 'significantly higher gross margins' than instruments. That recurring mix is what underpins the 61.8% gross margin and the visibility of forward revenue.

The balance sheet is sound rather than pristine. Total debt is modest (~$375M long-term + $75M current; the filing notes $398M drawn on the credit facility and a $250M term loan swapped to an effective 3.4% through 2028), liabilities/equity is just 1.09x, and operating cash flow of $1.18B (+27.2%) comfortably funds $125M of capex and the buyback. The one yellow flag is cash: down 37.5% to $180M, a direct consequence of returning $1.22B to shareholders. That's a capital-allocation choice, not stress — but it leaves thin liquidity, so the buyback pace is effectively gated by cash generation.